Asset Details
Do you wish to reserve the book?
International trends in erythropoietin use and hemoglobin levels in hemodialysis patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
International trends in erythropoietin use and hemoglobin levels in hemodialysis patients
Do you wish to request the book?
International trends in erythropoietin use and hemoglobin levels in hemodialysis patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
International trends in erythropoietin use and hemoglobin levels in hemodialysis patients
2010
Overview
Hemoglobin levels and the dose of erythropoiesis-stimulating agents (ESAs) have risen over time in hemodialysis patients within the United States. There are concerns that these trends may be driven by reimbursement policies that provide potential incentives to increase this use. To determine this we studied trends in the use of ESA and hemoglobin levels in hemodialysis patients and the relationship of these trends to the mode of reimbursement. Using the Dialysis Outcomes and Practice Patterns Study (DOPPS) database of hemodialysis we analyzed facility practices in over 300 randomly selected dialysis units in 12 countries. At each of three phases (years 1996–2001, 2002–2004, and 2005–present), we randomly selected over 7500 prevalent hemodialysis, hemofiltration, or hemodiafiltration patients. ESA usage rose significantly in every country studied except Belgium. All but Sweden demonstrated a substantial increase in hemoglobin levels. In 2005 more than 40% of patients had hemoglobin levels above the KDOQI upper target limit of 120g/l in all but Japan. These trends appeared to be independent of the manner of reimbursement even though the United States is the only country with significant financial incentives promoting increased use of these agents. Thus, our study found that prescribing higher doses of ESAs and achieving higher hemoglobin levels by physicians reflects a broad trend across DOPPS countries regardless of the reimbursement policies.
Publisher
Elsevier Inc,Nature Publishing Group,Elsevier Limited
Subject
/ Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
/ Biological and medical sciences
/ Emergency and intensive care: renal failure. Dialysis management
/ Erythropoietin - administration & dosage
/ erythropoietin/ec (Economics)
/ Humans
/ kidney failure, chronic/blood/economics/therapy
/ Nephrology. Urinary tract diseases
/ reimbursement mechanisms/economics/legislation & jurisprudence
